Connext Successfully Completes Dose Escalation Part of CNT201 Phase 1/2 Clinical Trial for Dupuytren's Contracture

Key Clinical Results and Future Plans Key Clinical Results and Future Plans Differentiation Through Innovative Recombinant Collagenase Currently, Endo's Xiaflex is the only commercially available collagenase injection for Dupuytren's contracture. CNT201 is being developed as an alternative to Xiaflex and is expected to significantly improve patient access to non-surgical treatment. Collagenase is originally produced by fermentation of the pathogenic microorganismClostridium...

Key Clinical Results and Future Plans

Differentiation Through Innovative Recombinant Collagenase

Currently, Endo's Xiaflex is the only commercially available collagenase injection for Dupuytren's contracture. CNT201 is being developed as an alternative to Xiaflex and is expected to significantly improve patient access to non-surgical treatment. Collagenase is originally produced by fermentation of the pathogenic microorganism Clostridium histolyticum, which carries inherent risks of contamination with various toxins. In contrast, CNT201 is the world's first recombinant collagenase therapeutic developed using genetic engineering technology, eliminating the risk of contamination from toxins or animal-derived substances. This ensures superior quality, consistent efficacy, and differentiated safety profiles.

Expanding Indications and Accelerating Global Drug Development

Connext is also pursuing a Phase 2 IND for Peyronie's disease, based on the same mechanism of action, and aims to obtain U.S. FDA IND clearance in 2025. Additional development for aesthetic indications such as cellulite is also underway.

Statement from Woo Jong Lee, CEO of Connext

"By confirming both safety and efficacy in the dose escalation part of Phase 1/2 study, CNT201 offers a new non-surgical treatment option for patients with Dupuytren's contracture. We aim to complete global new drug development with Phase 3 entry in 2027 and demonstrate the unique advantages of our innovative recombinant therapeutic," said Woo Jong Lee, CEO of Connext.

Contact:
Sangho Lee, Head of Innovation
[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/connext-successfully-completes-dose-escalation-part-of-cnt201-phase-12-clinical-trial-for-dupuytrens-contracture-302445024.html